Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients
- 20 September 2008
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 6 (10), 1655-1662
- https://doi.org/10.1111/j.1538-7836.2008.03095.x
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral AnticoagulationCirculation, 2007
- Genetic-based dosing in orthopedic patients beginning warfarin therapyBlood, 2007
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Evaluation of Genetic Factors for Warfarin Dose PredictionClinical Medicine & Research, 2007
- The impact of simvastatin on warfarin disposition and dose requirementsJournal of Thrombosis and Haemostasis, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarinThrombosis and Haemostasis, 2004
- Population pharmacokinetics of racemic warfarin in adult patientsJournal of Pharmacokinetics and Biopharmaceutics, 1985
- Flexible induction dose regimen for warfarin and prediction of maintenance dose.BMJ, 1984